Celsion Corporation (CLSN)
Stock Price:
$1.15 USD
-0.03 (-2.54%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
32.00M |
| Revenue (ttm) |
500,000 |
| Net Income (ttm) |
-19.54M |
| Shares Out |
33.22M |
| EPS (ttm) |
-0.83 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$1.15 |
| Previous Close |
$1.18 |
| Change ($) |
-0.03 |
| Change (%) |
-2.54% |
| Day's Open |
1.18 |
| Day's Range |
1.12 - 1.19 |
| Day's Volume |
1,199,292 |
| 52-Week Range |
0.69 - 6.50 |
More Stats
| Market Cap |
32.00M |
| Enterprise Value |
37.59M |
| Earnings Date (est) |
Aug 14, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
33.22M |
| Float |
28.83M |
| EPS (basic) |
-0.84 |
| EPS (diluted) |
-0.83 |
| FCF / Share |
-0.77 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.62M |
| Short Ratio |
0.30 |
| Short % of Float |
5.85% |
| Beta |
2.14 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
64.00 |
| PB Ratio |
2.42 |
| Revenue |
500,000 |
| Operating Income |
-20.47M |
| Net Income |
-19.54M |
| Free Cash Flow |
-19.91M |
| Net Cash |
-5.59M |
| Net Cash / Share |
-0.20 |
| Gross Margin |
-2,513.06% |
| Operating Margin |
-4,094.18% |
| Profit Margin |
-3,908.20% |
| FCF Margin |
-3,982.08% |
| ROA |
-30.34% |
| ROE |
-103.93% |
| ROIC |
-56.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
2 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$4.20*
(265.22% upside)
Low
4.00
Current: $1.15
High
4.41
Target: 4.20
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | - | 2.00 | - |
| Revenue Growth | 0% | 0% | 0% | 0% | 0% | 0% | - | - | - | - |
| Gross Profit | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | - | 2.00 | - |
| Operating Income | -20.57 | -21.07 | -18.47 | -20.65 | -20.85 | -24.72 | -15.41 | -22.14 | -23.02 | -19.64 |
| Net Income | -16.85 | -11.88 | -20.40 | -22.05 | -22.46 | -25.49 | -8.25 | -26.57 | -23.22 | -18.82 |
| Shares Outstanding | 21.83 | 17.58 | 7.63 | 1.85 | 1.56 | 1.32 | 0.97 | 0.55 | 0.33 | 0.20 |
| Earnings Per Share | -0.77 | -0.68 | -2.72 | -11.89 | -14.42 | -19.32 | -13.30 | -48.16 | -70.00 | -95.76 |
| Operating Cash Flow | -20.26 | -7.04 | -16.64 | -18.38 | -20.83 | -21.35 | -9.53 | -22.14 | -22.74 | -13.37 |
| Capital Expenditures | -0.35 | -0.14 | -0.04 | -0.06 | -0.11 | -0.67 | -0.06 | -0.61 | -0.57 | -0.01 |
| Free Cash Flow | -20.61 | -7.18 | -16.68 | -18.44 | -20.94 | -22.03 | -9.58 | -22.76 | -23.32 | -13.37 |
| Cash & Equivalents | 6.88 | 13.35 | 24.17 | 4.30 | 20.07 | 36.86 | 42.87 | 23.03 | 30.30 | 1.53 |
| Total Debt | 11.34 | 9.42 | - | 2.56 | 6.42 | 9.71 | 5.01 | 5.07 | 0.18 | 0.18 |
| Net Cash / Debt | -4.46 | 3.94 | 24.17 | 1.74 | 13.64 | 27.15 | 37.86 | 17.96 | 30.12 | 1.35 |
| Assets | 38.28 | 46.86 | 47.51 | 30.85 | 49.03 | 66.69 | 45.67 | 25.36 | 32.65 | 2.53 |
| Liabilities | 23.72 | 25.99 | 20.81 | 24.12 | 28.64 | 33.87 | 14.15 | 13.40 | 6.46 | 7.10 |
| Book Value | 14.56 | 20.86 | 26.70 | 6.73 | 20.39 | 32.83 | 31.52 | 11.96 | 26.19 | -4.58 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Celsion Corporation |
| Country |
United States |
| Employees |
29 |
| CEO |
Michael H. Tardugno |
Stock Information
| Ticker Symbol |
CLSN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CLSN |
| IPO Date |
March 5, 1985 |
Description
Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.